Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

58.41
-0.2400-0.41%
Pre-market: 58.25-0.1600-0.27%07:00 EDT
Volume:3.07M
Turnover:181.88M
Market Cap:14.47B
PE:18.37
High:61.14
Open:58.90
Low:58.40
Close:58.65
52wk High:61.14
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.73
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.85
PE(LYR):21.01

Loading ...

Exelixis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 07

Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says

MT Newswires Live
·
May 07

Stock Track | Exelixis Soars 5.99% in Pre-market on Analyst Upgrades and Strong Q1 Earnings

Stock Track
·
May 06

Goldman Sachs Remains a Buy on Exelixis (EXEL)

TIPRANKS
·
May 06

Exelixis (EXEL) Gets a Hold from Wells Fargo

TIPRANKS
·
May 06

Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50

TIPRANKS
·
May 06

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)

TIPRANKS
·
May 06

Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis (EXEL)

Simply Wall St.
·
May 06

Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality

TIPRANKS
·
May 06

Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Exelixis Posts Strong Q1 Results, Expands Share Buybacks

TIPRANKS
·
May 06

Exelixis Q1 revenue slightly beats estimates

Reuters
·
May 06

GUIDANCE: (EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.58B

MT Newswires Live
·
May 06

Exelixis Q1 FY26 GAAP diluted EPS climbs to $0.79; revenue rises to $610.8 million

Reuters
·
May 06

Exelixis Q1 Adj. EPS $0.87 Beats $0.70 Estimate, Sales $610.812M Beat $605.196M Estimate

Benzinga Earnings
·
May 06

BRIEF-Exelixis Q1 Revenue USD 610.8 Million Vs. IBES Estimate USD 605.2 Million

Reuters
·
May 06

Exelixis Guidance 2026 Total Revenues $2.525 Billion - $2.625 Billion

THOMSON REUTERS
·
May 06

Exelixis Inc - Maintains 2026 Financial Guidance

THOMSON REUTERS
·
May 06

Exelixis Inc - in May, Board Authorizes $750 Mln Stock Repurchase Program in May 2026

THOMSON REUTERS
·
May 06

Exelixis Inc - Initiates Stellar-201 Phase 2 Trial of Zanzalintinib in Recurrent Meningioma

THOMSON REUTERS
·
May 06